论文部分内容阅读
目的 :通过研究评价门静脉灌注IL Ⅱ治疗门静脉癌栓的疗效。方法 :B超引导下经皮门静脉穿刺灌注IL Ⅱ 1 0 0万单位 ,每周 1次 ,3次为一个疗程 ,每月一个疗程 ,共 3个疗程。结果 :PVTT消融疗效 :CR2 2 5 8% (7/ 31 )、PR32 2 6 % (1 0 / 31 )、NR35 4 8% (1 1 / 31 )、PD9 7% (3/ 31 )。生存期 6个月以内为 2 5 8% (8/ 31 )、6～ 1 2个月 5 4 8% (1 7/ 31 )、大于 1 2个月 1 9 3% (6 /31 )。大部分病人治疗后症状及体征均有好转。结论 :门静脉灌注IL Ⅱ治疗PVTT具有创伤小 ,可重复进行治疗等优点 ,拓宽了肝癌综合治疗方法。我们认为其不失为一个治疗门静脉癌栓的手段
Objective: To evaluate the efficacy of portal vein perfusion of IL Ⅱ in the treatment of portal vein tumor thrombus. Methods: Percutaneous portal vein puncture was performed with B-ultrasonography and perfusion of IL Ⅱ 10 million units once a week for 3 times for one course of treatment for one course per month for a total of 3 courses. Results: The curative effect of PVTT was CR2 25.8% (7/31), PR32 26% (10/31), NR35 48% (11/31) and PD9 7% (3/31). The survival time was 25.8% (8/31) in 6 months, 54.14% (17/31) in 6-12 months, and 13.3% (6/31) in 12 months. Most patients have improved symptoms and signs after treatment. Conclusion: Intravenous infusion of IL Ⅱ in treatment of PVTT has the advantages of small trauma, repeated treatment, and broadens the comprehensive treatment of liver cancer. We think it can be regarded as a means of treatment of portal vein tumor thrombus